89 related articles for article (PubMed ID: 2153442)
1. Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study.
Daly PF; Zugmaier G; Sandler D; Carpen M; Myers CE; Cohen JS
Cancer Res; 1990 Feb; 50(3):552-7. PubMed ID: 2153442
[TBL] [Abstract][Full Text] [Related]
2. 1-beta-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase.
Kucera GL; Capizzi RL
Cancer Res; 1992 Jul; 52(14):3886-91. PubMed ID: 1377599
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; RamÃrez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
4. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
5. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Glunde K; Jie C; Bhujwalla ZM
Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
[TBL] [Abstract][Full Text] [Related]
6. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
7. Alterations of choline phospholipid metabolism in ovarian tumor progression.
Iorio E; Mezzanzanica D; Alberti P; Spadaro F; Ramoni C; D'Ascenzo S; Millimaggi D; Pavan A; Dolo V; Canevari S; Podo F
Cancer Res; 2005 Oct; 65(20):9369-76. PubMed ID: 16230400
[TBL] [Abstract][Full Text] [Related]
8. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
9. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.
Sterin M; Cohen JS; Mardor Y; Berman E; Ringel I
Cancer Res; 2001 Oct; 61(20):7536-43. PubMed ID: 11606391
[TBL] [Abstract][Full Text] [Related]
10. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
11. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
White JC; Hines LH
Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
13. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
14. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis.
Katz-Brull R; Seger D; Rivenson-Segal D; Rushkin E; Degani H
Cancer Res; 2002 Apr; 62(7):1966-70. PubMed ID: 11929812
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
16. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
Gandhi V; Plunkett W
Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
[TBL] [Abstract][Full Text] [Related]
17. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples.
Morvan D; Demidem A; Papon J; De Latour M; Madelmont JC
Cancer Res; 2002 Mar; 62(6):1890-7. PubMed ID: 11912170
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study.
Singer S; Souza K; Thilly WG
Cancer Res; 1995 Nov; 55(22):5140-5. PubMed ID: 7585561
[TBL] [Abstract][Full Text] [Related]
19. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
Myers-Robfogel MW; Spataro AC
Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029
[TBL] [Abstract][Full Text] [Related]
20. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]